about
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypesHCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cellsHIV and malaria.Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patientsHost factors involved in low susceptibility to HIV infection.Rate and predictors of progression in elite and viremic HIV-1 controllers.Human leucocyte antigen (HLA)-DQB1*03:02 and HLA-A*02:01 have opposite patterns in their effects on susceptibility to HIV infection.The changing face of hepatitis C in the new era of direct-acting antivirals.Human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in an HIV-positive patient coinfected with human T lymphotropic virus type 2 following initiation of antiretroviral therapy.Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients.Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.Prevalence of HIV-1 dual infection in long-term nonprogressor-elite controllers.Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals.Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia.Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cART.Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.Pharmacogenetics of hepatitis C.Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline.[Adaptive cell immune response against the hepatitis C virus infection].Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART.Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers.Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection.Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy.Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?
P50
Q35768047-3D8F5D96-3BB8-49A6-8F63-DC2570A33618Q36316589-F76C2A80-F3C0-4AB3-B5E5-75A98DF2057BQ36908616-D45E3499-E1B2-4051-8617-DF11DB52303DQ36967081-B12CB5DF-DA78-4A8A-9DC7-47AEC4151C3EQ37230823-69F09D01-D8C9-47F2-AC5B-A2524EB23BBDQ37853875-CE04581F-05DC-4650-BC29-EE58744F5234Q38409790-0313C877-D23E-4A65-9DA9-DF16CA7FD63CQ38951922-39DAE5C1-9C8E-45BA-B4B9-713A466E5492Q39521142-063738BC-F2BB-40BF-9DDC-16198B2D9331Q39529753-0EB75265-D71A-44BF-9067-5490F5ED990FQ40228920-7FC6AA75-710B-4246-BFA6-CFB51593B183Q40394994-53DC4205-70C2-440D-B8CC-37212B1D5DB4Q40808386-D9CFEB41-37A6-494B-9EB9-F704327E799BQ41433750-DBE8BAD9-ADEB-455C-9DD7-6F5D23F26FEAQ42203170-CA37142E-BC95-4561-9500-50AB9410288DQ42234661-EDD73F95-6FC7-4DBE-A2D3-7CB03734A685Q42261289-CE48D9CC-E96F-449A-9E5E-E8DE6B563D4AQ42261321-FC118B0D-2DAA-4FB3-B721-C38DBE063F6BQ42284512-3702ABFD-68CB-47F6-8597-B310FD7D013EQ42287097-6033337A-94D6-43D9-B8F8-39AB2FEEACF7Q42977958-5105AA3F-7E2A-42EF-ADED-A4A6E527564FQ42981615-8D471F45-3D68-4346-952A-D7B9B566F3F3Q42985931-A3085FD3-74C7-4CD3-A0BB-8B33783EF546Q43000776-1835C727-4CCE-4AF0-A29B-F597F6B28BA2Q43034902-4062B9D7-AE3F-4D66-8256-987930AB1E5AQ43845101-355DEC8E-85E4-443F-BDDD-7351DCE01E15Q44539359-25AC5BFD-1783-4D6F-9E68-6B3FC6C21443Q45366419-A266CB94-5C2B-4913-A314-D6BD3873001AQ45375359-F683D033-6593-4A4F-A3D6-F7A381DECEE7Q46615239-F150525E-BD72-4E3A-BFDF-2D38756F98C7Q47150484-EF88E9DD-ADB4-4773-AD99-89DFEDB48B5DQ47174478-86C81CDE-3B08-44CF-99AD-C5AE286C8F82Q50553995-FD6C0573-800D-4187-BA7E-90F1CBFBD0A3Q50558142-65466295-018F-494B-ADE4-A9D9B99BCDD1Q50569944-6B757EC2-6411-4C96-840B-DC7C5F5569A7Q51033300-EA49DDA1-0D02-488A-8651-832B41C25F9AQ52680990-314A2C02-6C87-4F65-AE5D-79A3B451A486Q54259809-0CAFF3CF-6BDA-4B24-9561-0F8D54C4D3B9Q54940880-8D81DB48-BB51-4F44-8965-E5F188723FFFQ55396127-3B721B5A-A7F8-4DD5-8A20-16ACD9F0949A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Norma I Rallón
@en
Norma I Rallón
@nl
type
label
Norma I Rallón
@en
Norma I Rallón
@nl
prefLabel
Norma I Rallón
@en
Norma I Rallón
@nl
P31
P496
0000-0002-4643-247X